Novel Device used to Optimize Aerosol Drug Delivery for Pulmonary Hypertension Treatment

用于优化肺动脉高压治疗气雾剂药物输送的新型装置

• 批准号: 10080872
• 负责人: John E Porterfield
• 金额: $ 25.18万
• 依托单位: BRIDGESOURCE MEDICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10080872
• 关键词: Aerosols; Affect; Air Movements; Area; Arteries; Asthma; Back; Blood Circulation; Breathing; Bronchitis; Caliber; Cessation of life; Chronic Obstructive Airway Disease; Clinical; Clinical Research; Consult; Deposition; Device Designs; Devices; Diagnosis; Disease; Disease Management; Dose; Drug Delivery Systems; Drug Formulations; Ensure; Exhalation; Goals; Heart; Heart failure; Hour; Housing; Iloprost; Inhalation; Inhalation Therapy; Lead; Leadership; Left; Life; Life Expectancy; Lung; Lung diseases; Measurement; Medial; Medical; Nebulizer; Oral; Particle Size; Patients; Pattern; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Pharmacotherapy; Pharmacy facility; Pharyngeal structure; Phase; Physician Executives; Population; Principal Investigator; Prostaglandins; Pulmonary Hypertension; Radial; Radiolabeled; Research; Research Personnel; Resolution; Respiration Disorders; Respiratory Therapy; Saline; Small Business Innovation Research Grant; Speed; Spottings; System; Techniques; Testing; Texas; Time; Treprostinil; United States Food and Drug Administration; Universities; aerosolized; austin; base; commercialization; compliance behavior; dosage; effective therapy; experience; expiration; hypertension treatment; improved; improved outcome; mechanical force; medication administration; novel; older patient; outcome forecast; particle; pressure; professor; prototype; pulmonary arterial hypertension; respiratory; sensor; therapeutic target; tool; wasting

Abstract Aerosol inhalation therapy is one of the cornerstones of respiratory therapy. The size of airborne particles determines their deposition pattern within the lungs and therefore, the efficacy of inhalation therapy. In this Phase 1 SBIR project, BridgeSource Medical (BSM) proposes to develop a breath-adaptive nebulizer with variable aerosol droplet sizes and actuation times. This can be used to administer precise doses of pharmaceutical drugs to the systemic circulation with much greater efficiency than currently available aerosol delivery devices like small-volume adaptive aerosol delivery (AAD) nebulizers that require strict patient breath timing, but do not vary droplet size. The nebulizer would be particularly beneficial in the administration of medications to treat elderly patients with respiratory conditions such as pulmonary hypertension, where long treatment times and strict requirements on patient breathing lead to poor compliance. The ultimate goal will be to develop a clinical tool that would be approved by the Food and Drug Administration (FDA) as an effective system to nebulize several drug formulations targeted for patients who cannot easily comply with strict breathing maneuvers, such as the those with advanced lung disease.

摘要 雾化吸入疗法是呼吸疗法的基石之一。空中的大小 颗粒决定了它们在肺内的沉积模式，因此， 吸入疗法。在这个第一阶段的SBIR项目中，BridgeSource Medical(BSM)提议 开发一种呼吸适应性喷雾器，具有可变的气雾剂液滴大小和作用时间。 这可以用来给全身注射精确剂量的药物。 比目前可用的气雾剂输送设备(如 小容量自适应气雾剂(AAD)雾化器，需要严格的患者呼吸定时， 但不能改变液滴的大小。雾化喷雾器对政府特别有利。 治疗患有肺部等呼吸道疾病的老年患者的药物 高血压，治疗时间长，对患者呼吸的严格要求导致 合规性差。最终目标将是开发一种临床工具，该工具将被 食品和药物管理局(FDA)作为雾化几种药物的有效系统 针对那些不能轻易遵守严格呼吸动作的患者的配方， 比如那些患有晚期肺病的人。